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1 Zusammenfassung 
Eine simultane oder eine Hyperinfektion von bereits mit Hepatitis B Virus (HBV) 
infizierten Personen mit dem Hepatitis D Virus (HDV) verursacht die 
schwerwiegendste Form der chronischen Hepatitis, die Delta-Hepatitis. Obwohl die 
Replikation von HBV oftmals durch HDV unterdrückt wird, können in ko-infizierten 
Patienten hohe Titer beider Viren bestehen bleiben. Ziel dieser Arbeit war es, 
funktionell relevante molekulare Interaktionen zwischen dem Hepatitis B- und dem 
Hepatitis D-Virus zu identifizieren. Um die Interaktionen der beiden Viren zu 
untersuchen, wurden die kompletten Genome und die gesamten HDV-
proteinkodierenden (HDAg)  Sequenzen von 34 HDV-infizierten iranischen Patienten 
analysiert. Es wurden weiterhin Fall-Kontroll-Studien durchgeführt, bei denen die 
HBV-Genome von 17 HBV/HDV ko-infizierten Patienten mit detektierbarer HBV-DNA 
im Serum mit einer Kontrollgruppe von 34 HBV-infizierten Patienten verglichen 
wurde. Hierbei wurden Mutationen im kleinen Hüllprotein (S-HBsAg), der reversen 
Transkriptase (rt)-Domäne sowie den precore (PC) und basal core promoter (BCP)-
Regionen untersucht. Weiterhin wurden die funktionalen Auswirkungen von häufig 
auftretenden HBV-Mutationen, wie die Lamivudine (LAM)-Resistenz-Mutanten 
(rtM204V/I und rtL180M) alleine oder zusammen mit Immunevasionsmutanten 
(sP120T, sG145R), PC (G1896A)- oder BCP (A1762T/G1764A)-Mutationen, auf die 
Replikationsfähigkeit von HBV und HDV analysiert. 
Phylogenetische Studien des kompletten HDV und L-HDAg-Isolaten zeigten, 
dass alle Stämme mit dem Genotyp 1 gruppierten. Weiterhin konnten ich einige 
nicht-synonyme Mutationen in immunogenen Epitopen von L-HDAg beobachten, 
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welche von CD8 T-Zellen und B-Zellen erkannt werden. Von den konsekutiv 
HBV/HDV-infizierten Patienten (71 Serumproben), konnte bei 24 HBV-Replikation 
detektiert werden und HBV in 17 Fällen erfolgreich sequenziert werden. In HDV-
infizierten Patienten konnten neben dem HBV-Genotyp D auch charakteristische 
Aminosäuresubstitutionen in den zytoplasmatischen Domänen (CYL-I and II) von 
HBsAg detektiert werden. Eine ko-Infektion mit HDV hatte keinen Einfluss auf die 
Replikation der HBV Polymerase- oder der Immunevasionsmutanten, aber reduzierte 
signifikant die Replikationsfähigkeit der Stämme mit PC- oder BCP-Mutationen. 
Mutanten der HBV Polymerase oder des Hüllproteins beeinflussten die Replikation 
von HDV in vitro.  
Somit konnten im Rahmen dieser Arbeit funktionale Interaktionen zwischen 
verschiedenen HBV-Mutanten und HDV aufgedeckt werden, welche mit einem 
ausgeprägten Mutationsmuster von HDV und HBV in ko-infizierten Patienten 
einhergingen. 
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2 Abstract 
Delta hepatitis, hepatitis D virus (HDV) co- or super-infection in hepatitis B virus 
(HBV) infected individuals, is the most severe form of chronic hepatitis. Although 
HDV oftentimes suppresses HBV replication, also high levels of HDV and HBV can 
persist in co-infected individuals. In this study I aimed at identifying functionally 
relevant molecular interactions between HBV and HDV. To investigate HBV and delta 
virus interactions, I analysed the HDV full-length genome as well as the entire HDV 
protein (HDAg) coding sequences of 34 HDV-infected Iranian patients. I also 
conducted a case-control analysis to compare the HBV genome of 17 HBV/HDV co-
infected patients with detectable HBV-DNA in their serum with a control group of HBV 
mono-infected individuals (34 sequences) for mutations in S-HBsAg, reverse 
transcriptase (rt) domain and precore (PC) or basal core promoter (BCP) regions. 
The functional effects of commonly observed HBV mutations, including Lamivudine 
(LAM)-resistance mutations (rtM204V/I and rtL180M) alone and together with 
immune escape mutants (sP120T, sG145R), PC (G1896A) and BCP 
(A1762T/G1764A) mutations, on the replicative capacity of both HBV and HDV, were 
also investigated. 
Phylogenetic analyses of full-length HDV and L-HDAg isolates revealed that all 
strains clustered with genotype 1. I also observed several non-synonymous 
mutations that affected immunogenic epitopes of L-HDAg towards CD8 T-cell- and B-
cell-driven immune responses. Among the consecutive HBV/HDV infected patients 
(71 serum samples), 24 had detectable HBV replication with successful HBV 
sequencing in 17 cases. HBV genotype D was detected in HDV-infected patients, 
alongside characteristic amino acid substitutions in cytosolic domains (CYL-I and II) 
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of HBsAg. On a functional level, HDV co-infection did not affect replication of HBV 
polymerase or immune escape mutants, but significantly reduced replicative capacity 
of strains containing PC or BCP mutations. HBV polymerase or surface antigen 
mutants affected HDV replication in vitro. In conclusion this study revealed functional 
interactions between HBV mutants and HDV, in line with a distinct mutational pattern 
of HDV and HBV in co-infected patients.   
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3 Introduction 
The hepatitis D or delta virus (HDV) causes chronic or fulminant hepatitis in 
hepatitis B virus (HBV) infected individuals. HDV infection may occur as a co- or 
super-infection, which often times leads to an acute or chronic hepatitis (depending 
on the type of infection) with more severe outcome of the disease 1. HDV requires an 
obligatory helper function to propagate 1,2. This helper function is usually provided 
through HBV by sharing its envelope proteins 1. Experimentally, the “delta virus” can 
also infect chimpanzees or woodchucks that have already been infected with HBV or 
woodchuck hepatitis virus (WHV), respectively 3. HBV/HDV co-infection is a clinically 
very deleterious condition as it commonly leads to progression of hepatic fibrosis, 
cirrhosis and increases the risk of hepatocellular carcinoma (HCC) 4. Due to global 
HBV vaccination programs since 1990s, HDV infection has been relatively well 
controlled in European countries especially in Western Europe 5. In contrast, several 
countries in the Middle East are considered endemic regions for HDV infections 6-10. 
The mechanism by which HDV promotes hepatic malignancies are unclear, however, 
it has been shown that the virus has negative effects on hepatocytes’ growth and 
viability 11. Some in vivo studies have shown that other Orthohepadnaviridae 
members like WHV can also play the same role as HBV 3. There are some 
arguments that interactions between HDV and its helper virus might not be limited to 
surface protein supplies, but also to other unknown mechanisms 12. The molecular 
interaction sites between HBV and HDV as well as the mechanisms, which are 
employed by these viruses to facilitate or inhibit each other’s replication, are only 
partially understood at present. 
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3.1 HBV virion structure and genotypes 
HBV is a DNA virus that belongs to the family of hepadnaviridae. There are 
some common features among the members of hepadnaviridae including their 
partially double stranded DNA, viral DNA polymerase with reverse transcriptase 
activity, an intermediate pregenomic RNA (pgRNA) which serves as a template for 
DNA replication and a very specific attitude for certain species and tissues 13. There 
are eight genotypes of HBV (from A to H) with different geographical distributions, 
severity of disease and responses to treatment due to the structural and functional 
differences between genotypes 14,15. For instance, an increased risk of HBV 
recurrence and developing HCC has been reported for patients infected with HBV 
genotype C compared to genotype B and HBV genotype D compared to genotype A. 
There is also a lower response to interferon-alpha (IFN-α) treatment in patients 
infected with HBV genotypes C and D compared to those with genotypes A and B 16. 
HBV genotype D with a worldwide distribution is the most prevalent HBV genotype in 
Middle East, parts of India and Mediterranean countries 17. 
From a structural point of view, the infectious HBV virion or Dane particle is a 
spherical enveloped structure with a diameter of 42 nm 13. The virus has a 3.2 Kb 
partially double stranded DNA as its genomic material (Figure 1). HBV subviral 
particles (SVPs) with a diameter of 20 nm lack nucleocapsid and bud from the post-
ER pre-Golgi membranes. SVPs are highly overproduced compared to complete 
virions during an infection 18,19. One important feature in HBV genome is the 
overlapping positioning of its genes, which provide a condition for maximal usage of 
the genome in minimal space. This feature also leads to simultaneous mutation/s in 
the overlapping domains. 
Introduction 
___________________________________________________________________ 
7 
 
 
 
Figure 1: Schematic structure of hepatitis B 
virus (HBV) 
The viral nucleocapsid (NCP), consisted of 
HBV partially double-stranded DNA and core 
proteins, is surrounded by a lipid bilayer, 
containing large, medium and small HBV 
surface antigens (L, M, S-HBsAgs, 
respectively). 
 
3.2 HBV genomic organization 
Five major HBV RNA species are produced under the control of four promoters 
known as (a) enhancer II (Enh II)/basal core promoter (BCP), (b) large HBV surface 
antigen (L-HBsAg), (c) middle surface antigen (M-HBsAg) and (d) enhancer I (Enh 
I)/X gene promoters. These include the 3.5 Kb precore RNA (pcRNA) and pgRNA 
which encode HBeAg (pcDNA) and HBV core protein (HBcAg) and polymerase 
(pgRNA). The other RNAs are a 2.4 Kb transcript that encodes L-HBsAg, the 2.1 Kb 
RNA which is translated to medium (M-) and small (S-) HBsAgs and the 0.7 Kb RNA 
which produces the X protein.  
The pgRNA is also applied as the template for reverse transcription of HBV 
genome (Figure 2A) 20,21. 
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Figure 2: HBV genome structure and clinically relevant mutation sites 
(A) HBV contains a 3.2Kb partially double-stranded DNA genome with four promoters which produce 
five RNA species including precore and pgRNA (3.5Kb), L-HBsAg RNA (2.4Kb), medium (M-) and 
small (S-) HBsAg RNA (2.1Kb) and the HBx-RNA (0.7Kb). (B) The polymerase domains and the 
location of the codons in HBV reverse transcriptase (rt), related to antiviral drug resistance are shown. 
(C) The HBsAg domains and the codons in antigenic (Ag) loop associated with immune-escape 
mutations are indicated. Schematic localizations of HBsAg domains in the endoplasmic reticulum (ER) 
membrane are displayed. Two transmembrane topologies for L-HBsAg are represented. The pre-S1 
domain may reside on the cytoplasmic side of the ER membrane or translocate into the ER lumen. (D) 
HBV core gene contains precore (PC) and core domains with two in frame ATGs for translation 
initiation of HBeAg and core protein, respectively. The G1896A (along with C1858T in genotype A) 
terminates HBeAg expression by creating a stop codon in the PC domain (TGG) and the 
A1762T/G1764A mutations in the BCP domain reduce HBeAg transcription.   
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3.3 HBV proteins 
3.3.1 HBV polymerase 
The polymerase open reading frame (ORF), which is the longest ORF in HBV 
genome, encodes a viral polymerase with three catalytic subdomains known as 
terminal protein-priming domain, reverse transcriptase (rt) domain with DNA-
polymerase activity and RNase H domain (Figure 2B) 22. This enzyme uses HBV 
pgRNA as a template to synthesize viral DNA through RNA-dependent DNA-
polymerase activity and is the main target for anti-HBV antiviral therapy using 
nucleos(t)ide analogue (NA) RT inhibitors 23. Long term application of NA treatment 
results in the accumulation of mutations in RT and emergence of drug resistant 
isolates 24. Especially the “first generation” antiviral drugs lamivudine (LAM) and 
adefovir (ADV), which are still widely used worldwide, bear a high risk of selecting 
mutations in the HBV polymerase region that confer drug resistance.  
The most common mutations associated with LAM resistance occur in the 
YMDD motif of the C domain of HBV polymerase region (Figure 2B) causing a 
methionine change with either isoleucine (rtM204I) or valine (rtM204V). In most of the 
cases rtM204V mutation is not present alone but linked with a leucine to methionine 
exchange at position 180 (rtL180M) 25. From a molecular level, it is well known that 
many drug-resistance associated polymerase mutations, such as LAM resistance, 
reduce the replication efficacy of HBV 26.  
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3.3.2 HBV surface antigens 
HBV encodes three surface proteins with different initiation sites for 
transcription from envelope ORF. These proteins are L-, M- and S-HBsAgs (42 KDa, 
33 KDa and 27 KDa, respectively) 27. The S-HBsAg is encoded by the S domain 
which is the common part among all three proteins. As an integral protein, S-HBsAg 
(226 amino acids) is anchored in the lipid bilayer of the endoplasmic reticulum (ER) 
through its highly hydrophobic N-terminal (residues 4-28 and 80-100) and C-terminal 
(residues 165-226) transmembrane domains (TMDs). It also includes an antigenic 
loop (Ag loop, residues 101-164) with immunodominant and immunoprotective 
epitopes located in a highly conserved domain known as ‘a’ determinant (residues 
124 to 147) facing the ER lumen 28-30. Mutations in the Ag loop may affect the 
antigenicity of HBsAg such that protective antibodies against HBs cannot bind this 
domain anymore. The sG145R and sP120T (s stands for the amino acid position in 
the surface protein) are the most common immune escape mutations with reduced 
affinity for anti-HBs 31. HBV variants with such mutations are called ‘immune escape’ 
isolates. The rest of residues located between TMDs face the cytoplasm and are 
called cytosolic loops (CYLs). These are expected to be residues 29 to 79 (CYL-I) 
and 194 to 201 (CYL-II) 32. The M-HBsAg (281 amino acids), contains the whole S-
HBsAg plus an N-terminal preS2 region facing the ER lumen. The L-HBsAg (389-400 
amino acids), contains preS1, preS2 (preS) and S domains 33. This protein has two 
conformations based on the positioning of preS in ER membrane towards the 
cytoplasm (for virion formation) or ER lumen (Figure 2C) 32. The occasional genotype 
specific post translational modifications (PTMs) of the surface antigen amino acids 
will make some changes in protein structures and subsequently in their functions 13. 
In the ER lumen Asn-146 of the ‘a’ determinant may undergo glycosylation by N-
Introduction 
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glycosyltransferases localized within this space. The glycosylated S-HBsAg is known 
as p27 and the non-glycosylated form as p24 13. The N-terminal pre-S2 region of the 
M-HBsAg also faces the ER lumen making its Asn-4 potent for glycosylation 13. 
Based on glycosylations at Asn-4 and/or Asn-146, M-HBs may appear in three forms; 
non-glycosylated (p30), mono-glycosylated (gp 33) and bi-glycosylated (gp 36) 34-36.  
3.3.3 HBV core and e antigens 
HBV core gene is divided to the precore (PC) and core domains by two in frame 
ATGs for translation initiation. Translation of PC domain results in the non-structural 
HBeAg production, which is released to the blood stream of the infected patients as a 
secretory protein. While HBeAg is not required for HBV replication in in vitro systems, 
an immune response against it results in an effective suppression of viral replication, 
which is subsequently associated with the selection of HBV isolates with less or no 
HBeAg expression 37. Two major mutations have been reported which cause reduced 
or blocked HBeAg expression. These include a G1896A exchange, which creates a 
stop codon in codon 28 of the PC domain (TGG), and the A1762T/G1764A mutations 
in the BCP domain, which reduce transcription factor binding and therefore decrease 
PC-RNA transcription and HBeAg expression associated with enhanced HBV 
replication (Figure 2D) 37,38.  
The core protein is responsible for nucleocapsid formation through forming 
connections with HBV pgRNA-polymerase complex. HBcAg is consisted of 183 or 
185 amino acids depending on HBV genotype. The N-terminal domain of the protein 
is in charge of nucleocapsid self-assembly, and the C-terminal domain is involved in 
pgRNA binding due the positive charge of this area resulted from arginine residues 
39. 
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3.3.4 HBV X protein 
The HBxAg coding gene (462 nucleotides) is the smallest gene of HBV. HBxAg 
is required for infection establishment in patients but not essential for HBV replication 
in transfected cells 40. 
The protein is present in the cytoplasm and to a lesser extent in the nucleus of 
infected cells. HBx coding region on HBV genome overlaps with the BCP domain so 
the altered HBV replication due to BCP mutations has been also attributed to 
modified HBxAg structure 37. This protein is known as a transcriptional transactivator, 
which can activate several cellular and viral promoters and enhancers through 
protein-protein interactions 40.  
3.4 HBV life cycle 
HBV uses its Pre-S1 domain of the L-HBsAg for hepatocyte receptor-binding 
followed by membrane fusion and cell entry 41. The life cycle of HBV in the cell 
consists of two key steps; (a) generation of HBV covalently closed circular DNA 
(cccDNA) from partially double stranded relaxed-circular DNA (RC-DNA) to be used 
as a template for subsequent viral RNA transcription and (b) reverse transcription of 
pgRNA inside the nucleocapsids to form RC-DNA 39. Schematic representation of 
HBV replication is shown in Figure 3. 
When HBV capsid found its way to the nucleus of infected cells, it dissociates 
and the RC-DNA is converted to cccDNA or viral mini-chromosome (episomal DNA). 
The cccDNA acts as the main transcriptional template for the synthesis of pgRNA 
and other subgenomic RNAs 42. The pgRNA serves as a template for both translation 
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and reverse transcription processes. It is an over length RNA (3.5 Kb) that contains a 
second copy of direct repeat 1 (DR1), the ε signal (a cis-element encapsidation signal 
on the pgRNA) and a poly-A tail. RNA polymerase II is responsible for the 
transcription of all HBV RNAs 39. 
HBV polymerase binds to the ε signal, and the pgRNA-polymerase complex is 
packed in the lumen of assembling capsids. The ε-polymerase binding leads also to 
the initiation of reverse transcription process starting by minus (-)-DNA strand 
synthesis from pgRNA 43. The complementary plus (+)-DNA strand is then made from 
the (-)-DNA (partially) to generate RC-DNA. After the reverse transcription is 
completed and the (-)-DNA strand is synthesized, the nucleocapsid can either 
interact with HBV surface proteins followed by secretion from the cells or they can re-
deliver their RC-DNA to the nucleus to make a pool of cccDNA. The mature HBV 
nucleocapsid complexes then are delivered to the post-ER, pre-Golgi-compartments 
to interact with the surface proteins through the preS1 and 2 domains of L-HBsAg 
with cytosolic orientation in ER as well as the CYL-I in the S-HBsAg 44 followed by 
budding of the virions from the cell membrane 39.    
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Figure 3: HBV life cycle 
HBV binds to the cell (co-)receptors on the surface of the hepatocytes through its HBsAg pre-S1 
domain. After entry, viral cores disassemble and genomic DNA is transported to the nucleus. (3) The 
viral relaxed-circular DNA (RC-DNA) is converted to covalently closed circular DNA (cccDNA), most 
probably by host cell enzymes, (4) to be applied as the template for transcription of all viral mRNAs. 
(5) The longest HBV mRNA, pgRNA (3.5Kb), serves as a template for reverse transcription as well as 
translation to three HBV proteins; polymerase, core and (6) HBeAg which is released to the blood 
stream. (7) Aggregation of pgRNA, polymerase and core proteins in the cytoplasm leads to the 
formation of HBV nucleocapsids. Inside these particles, pgRNA is subjected to the reverse 
transcription process through reverse transcriptase activity of the polymerase. (8) Three viral envelope 
proteins are translated from the 2.4 and 2.1Kb mRNAs and reside on the endoplasmic reticulum (ER) 
membrane for post translational modification. (9) After budding from the post-ER pre-golgi membrane, 
part of HBsAg molecules participate in HBV nucleocapsid envelopment. (10) HBV nucleocapsids may 
either return to the nucleus to continue the cccDNA synthesis procedure or (11) segregate into the 
secretory pathway through interaction with envelope proteins. (12) The HBx proteins, which are 
translated from the smallest HBV mRNA (0.7kb), head to the nucleus of the cells to regulate HBV 
replication.   
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3.5 HDV viral structure, proteins and genotypes 
HDV, having a spherical shape and a virion size of 36 nm, is a satellite virus of 
HBV with a circular RNA of negative polarity 1. With respect to the size of the genome 
(1.7 Kb RNA), the rolling circle mechanism of replication and its high GC nucleotide 
content, HDV  is very unique among animal viruses and looks very similar to viroids 
(a family of helper-independent plant pathogens) 45.  
The HDV ribonucleoprotein (RNP) is surrounded by a mixture of host cell-
derived lipids and HBV surface proteins (HBsAg) 46. HDV has a small single stranded 
RNA genome of 1679 nucleotides. Due to the high degree of intramolecular base 
pairing in the HDV genome, the RNA folds to an un-branched, rod like structure 
(Figure 4) 47.  
 
Figure 4: Schematic structure of hepatitis D virus 
(HDV) 
HDV ribonucleoprotein (RNP) in surrounded by a 
lipid bilayer from the host cell, containing HBV 
envelope proteins. RNP: ribonucleoprotein, HBsAg: 
HBV surface antigen.  
 
 
 
HDV genomic RNA (G-RNA) is transcribed to an intermediate form, called anti-
genomic RNA (AG-RNA), in the nucleolus of the infected cells and through cellular 
RNA polymerases (Figure 5A). Phylogenetically, eight different clades of HDV have  
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Figure 5: HDV genome and protein structure  
(A) HDV genomic (G) and anti-genomic (AG) RNA strands with 1.7 Kb lengths. HDV genome consists 
of three main domains; the HDAg coding domain, the hyper variable domain and the ribozyme domain 
with auto-cleavage activity. HDV anti-genomic strand serves as an intermediate template for genomic 
strand transcription via cellular RNA polymerase II. The RNA editing site in HDAg coding domain 
denotes the edition site, which results in translation continuation and L-HDAg expression. (B) The 
schematic domains of L-HDAg and its post translational modification sites are shown. G-RNA: 
genomic RNA, AG-RNA: antigenomic RNA, RBD: RNA binding domain; CCD: coiled coil domain; NLS: 
nuclear localization signal; P: Phosphorylation; M: Methylation; A: Acetylation; I: Isoprenylation. 
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been introduced (genotypes 1 to 8) from different parts of the world, with distinct 
geographical regions and different outcomes of the diseases 1,48. 
HDV’s circular RNA forms a complex with two virally encoded proteins, small 
(195 amino acids) and large (214 amino acids) HDV-antigens (S-HDAg or p24, and 
L-HDAg or p27, respectively) 1. Delta proteins have identical amino acids except for 
19 additional residues at the C-terminus of L-HDAg 46. The small delta protein acts as 
a trans-activator for initiation of G-RNA replication 49. L-HDAg is a late protein which 
inhibits viral RNA replication and transcription of viral proteins, interacts with HBV 
surface antigens and accelerates the assembly of new virions 1. The capacity of 
binding to HBsAg is not only limited to L-HDAg protein but also occurs with S-HDAg. 
In fact, in the presence of S-HDAg the packaging level of HDV raises up to 3 to 4 fold 
46,50. Moreover, there is a conserved molar ratio of delta antigen to G-RNA of HDV in 
infected liver tissues as well as in HDV particles 50.  
Both S- and L-HDAgs undergo some PTMs like methylation, acetylation and 
phosphorylation. These modifications seem to be essential for HDV proteins to 
mediate HDV RNA transcription and HDV RNP complex envelopment. Some amino 
acid residues in S- and L-HDAg appear to be critical for the modification process. 
Among these residues Arg-13, Lys-72 and Ser-177 in S-HDAg undergo methylation, 
acetylation and phosphorylation, respectively 51-53. There are also multiple lysin 
residues throughout the whole S-HDAg as well as 66 amino acids at the N-terminal 
part of this protein which act as sumoylation sites of the protein. Sumoylation is a 
reversible process, which has implications for cell cycle progression, nuclear import, 
regulation of transcription, protein turnover and other cell biology functions. In case of 
HDV, sumoylation enhances G-RNA and mRNA synthesis by unknown mechanism 
but has no effect on AG-RNA synthesis 2. 
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In L-HDAg, Cys-211 gets isoprenylated for virus assembly 54. Deletion of 15 
amino acids upstream of the isoprenylation site would also lead to the eradication of 
viral replication (Figure 5B) 55. 
3.6 HDV replication 
The replication cycle of HDV is summarized in Figure 6. N-terminal residues of 
L-HBsAg mediate the entry of HDV into the hepatocytes 56. Once delta virus enters 
the cell it gets uncoated, and the accompanying S-HDAg leads the HDV 
nucleoprotein complex to the cell’s nucleus 47. HDV has a mechanism of rolling circle 
amplification. For this, the virus needs an RNA-dependent RNA polymerase activity, 
which in the majority of RNA viruses, but not in the case of HDV, is carried out by 
virally encoded enzymes. Exceptionally, the delta hepatitis virus is capable of using 
host RNA polymerases to amplify its genome 57. The HDV genomic strand undergoes 
RNA-dependent RNA synthesis, more likely by nucleolar RNA polymerase-I 1, to 
produce multimeric full-length intermediate RNAs or AG-RNAs. These molecules 
then serve as templates for cellular RNA polymerase-II to generate HDV G-RNA 
again through another rolling circle step 47. Both genomic and anti-genomic strands 
of HDV contain 85 nucleotides with ribozyme activity which enables the virus to self-
cleavage and to ligate its circular RNA (Figure 5A) 58. G-RNA is also transcribed into 
an mRNA (0.8 kb) which encodes HDAgs. This step distinguishes HDV from viroids, 
since they do not produce any protein 45. This event has also been shown to take 
place in the nucleus, the same place at which G-RNA synthesis happens 2. It means 
that different cellular machineries are mediating HDV G-RNA/mRNA and HDV AG-
RNA synthesis, which are localized in the nucleus and nucleolus of the host cells, 
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respectively 59. During small HDAg production, an RNA editing event happens at 
position 1012 by double-stranded RNA specific adenosine deaminase (ADAR), 
resulting in alteration of the stop codon of the S-HDAg ORF and translation extension 
for additional 19 amino acids 60. The extra 19 amino acid sequence of p27 is poorly 
conserved among different HDV isolates and thus has been used as an indicator for 
HDV genotyping 58. However, a much conserved CXXX motif inside this region 
causes prenylation of L-HDAg and facilitates protein-protein interactions 61,62. 
Defective mutants of this motif are not able to interact with HBsAg and to be 
packaged 62. Expression of L-HDAg initiates interactions with HBV surface proteins, 
HDV-RNP encapsidation and subsequent enveloped HDV-virion release from 
hepatocytes 46. 
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Figure 6: HDV life cycle in hepatocytes in the presence of HBV  
Summary of the current concept of hepatitis D virus (HDV) replication cycle. (1) The entry of HDV 
particles into hepatocytes is mediated by the attachment of hepatitis B virus (HBV) surface antigens 
coating HDV nucleoprotein to the host cell receptors, followed by endocytosis and uncoating of the 
virions. (2) HDV nucleoprotein complex is leaded to the nucleus by accompanying S-HDAg, then the 
complex arrives to the nucleolus where RNA polymerase I exists. (3) Multimeric full-length 
antigenomic RNAs (AG-RNAs) are transcribed from HDV genomic RNA, likely by RNA polymerase I. 
Circular AG-RNA molecules which are created by ribozyme activities of AG-RNA itself move to the 
nucleoplasm. (4) AG-strands serve as templates for RNA polymerase II. (5a) RNA polymerase II starts 
generating mRNA from genomic strands and (5b) full-length transcripts from AG-strands. (6) Due to 
RNA editing at position 1012 of S-HDAg exerted by double-stranded RNA-specific adenosine 
deaminase, the open reading frame of these mRNA molecules extends for additional 19 amino acids, 
which lead to the production of large delta antigen. (7, 8) mRNA molecules coding for small and large 
delta antigens move to the cytoplasm and are translated to relevant proteins. Small delta antigens 
activate genomic RNA replication, while large proteins promote virion assembly. (9) Viral proteins form 
nucleoprotein complexes with HDV genomic RNAs. (10) L-HDAg in HDV ribonucleoprotein complex 
interacts with existing HBV surface proteins in the cell. (11) After HDV encapsidation by HBV surface 
proteins, (12) complete virions leave the cell through exocytosis. (A) HBV surface proteins bud 
through the endoplasmic reticulum (ER) or golgi body membranes of the host cell 
1
.  
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3.7 Molecular interactions between HBV and HDV 
Although the direct contact between HBsAg and HDAg for HDV virion 
envelopment can be considered the main interaction between HBV and HDV, other 
less well understood mechanisms may also interfere with the replication of both 
viruses in infected cells 12.  
Since the surface protein coding region of HBV overlaps with its polymerase 
encoding domain, any mutation in this region may affect both polymerase and HBsAg 
activities 63. In fact, mutations in the HBV polymerase gene that also affect 
correspondingly the HBV surface antigen coding region may have effects on HBV as 
well as on HDV replication efficacy. Not all consequences of HBV mutations for 
HBV/HDV viral replication are currently understood, but limited data exist for some of 
the most common clinical variants (Table 1). While the LAM-resistance mutant 
rtM204V improves HDV secretion, another resistance-conferring mutant like rtM204I 
(corresponds to sW196L/S/stop) diminishes HDV production 63, which is due to the 
importance of the codon 196 in the HBV surface antigen for HDV packaging 64. Also, 
it has been shown that mutations in C-terminal region of HBV envelope proteins 
(especially between amino acid residues 163 to 224) can severely reduce HDV 
assembly 65. HBsAg mutations, selected by antiviral agents, are also located in this 
region. These mutations can affect the level of HDV virion secretion out of the cells in 
in vitro experiments 63,65. Although it is known that HBV/HDV coinfected patients have 
an unfavorable clinical outcome, the exact role of HBV and HDV in liver disease 
progression has been controversially discussed, because contrasting results have 
been published about the role of each one of the viruses 50,66. Some authors 
suggested that the underlying HBV infection is aggravated by concomitant presence 
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of HDV in hepatocytes with synergistic deleterious effects on cell survival 66,67, while 
others indicated that HDV, which often suppresses HBV, is most critical for liver 
disease and malignant transformation 11,50,66. 
Table 1: Molecular interactions between HBV and HDV 
The table summarizes findings from previous clinical or molecular studies, modified from 
1
. 
HBV polymerase 
mutation(s) 
Corresponding 
HBsAg 
mutation(s) 
Clinical relevance Effect(s) on HDV 
rtM204V  sI195M(A) LAM resistance Enhanced HDV secretion 
rtM204I  sW196L/S/stop LAM resistance S, L: no HDV secretion 
rtD205H  sW196F 
Selected during LAM treatment with 
reduced binding to anti-HBsAg 
antibodies 
Reduced HDV secretion 
rtV173L  sE164D 
Selected during LAM treatment with 
reduced binding to anti-HBsAg 
antibodies 
Reduced HDV secretion 
rtV173L/rtM204V  sE164D/sI195M 
Selected during LAM treatment with 
reduced binding to anti-HBsAg 
antibodies 
Support HDV secretion 
 
From a molecular point of view, it is very likely that both viruses do not replicate 
independent from one another, but modulate each other’s replication level and also 
pathogenicity 12. Suppressed HBV replication, but also high or fluctuating loads of 
both viruses in the serum of co-infected individuals have been reported 12,66. A recent 
longitudinal study investigating quantitatively HBV and HDV viral loads in co-infected 
patients showed that in spite of cross-sectional studies, in which there is a significant 
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positive association between HBsAg level and HBV-DNA or HDV-RNA, HBsAg has 
longitudinally fluctuating levels in the presence of HDV 66. Apparently, there is not 
always an inhibitory effect of HDV on HBV replication, as sometimes HBV shows 
significant inhibitory actions on HDV in HBV/HDV double infection as well, indicating 
ongoing and dynamic interactions between HBV and HDV in infected cells 66.  
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4 Aims of the study 
It is well known that HDV co-infection oftentimes suppresses HBV replication in 
patients, although also high levels of HDV and HBV isolates can persist in co-infected 
individuals. Some studies have investigated the prevalence and effects of HBV 
genome mutations, especially HBsAg alterations, on clinical outcomes and replicative 
capacity of HDV, but there are very few studies on HBV replication, especially 
mutants of HBV, in the presence of HDV. Substitutions in the surface antigen or 
polymerase gene of HBV as well as mutations related to HBeAg negativity, such as 
PC or BCP mutations, may dramatically affect the replicative capacity of HBV. The 
effects of such PC/BCP mutations, although frequently found in HBV infected 
patients, on replication of HBV and HDV in double infected cells using in vitro models 
are currently unclear .  
Based on previous studies I hypothesized that HBV and HDV genomes may 
adapt to the co-infection. To investigate this concept, I decided to analyse HBV and 
HDV genomes from a set of HBV and HBV/HDV infected patients from different parts 
of Iran, an endemic country for HDV infection, followed by a further analysis of the 
functional effects of commonly occurring HBV mutations, including LAM- resistance 
mutations (rtM204V/I and rtL180M) alone and together with immune escape mutants 
(sP120T, sG145R), PC (G1896A) and BCP (A1762T/G1764A) mutations, on the 
replicative capacity of both HBV and HDV.  
To test the hypothesis of viral adaptation to co-infection, the following questions 
were addressed in detail:  
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- At which rate the mutations in structural (for HBV and HDV) and enzymatic (for 
HBV) domains of the viruses occur in collected serum samples? 
- Which domains of HDAg and HBsAg genes from clinically provided samples 
are subjected to high rate of mutations and therefore under the pressure of 
positive selection? 
- How does co-infection with HDV affect the replicative capacity of the clinically 
frequent single (S) and double (D) LAM-resistance mutations (SM: rtM204I 
and DM: rtM204V+rtL180M) and their combination with immune-escape 
variants (sP120T+LAM-S, DM and sG145R+LAM-S, DM) and PC (G1896A) 
and BCP (A1762T/G1764A) mutations in HBV/HDV double-transfected cells 
compared to HBV mono-transfection control assays? 
- How does co-infection with HBV mutants affect the replication of HDV wild 
type virus in vitro? 
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5 Material and methods 
5.1 Materials 
5.1.1 Reagents and chemicals 
Table 2: Reagents and chemicals 
Acetic acid (glacial) Merck (Darmstadt, Germany) 
Acetic acid sodium salt AppliChem (Darmstadt, Germany) 
Beta-mercaptoethanol (BME) Sigma-Aldrich (St. Louis, USA) 
N,N-Bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid (BES) 
Sigma-Aldrich (St. Louis, USA) 
Bovine serum albumin (BSA)  Sigma-Aldrich (St. Louis, USA) 
Calcium chloride dihydrate  Merck (Darmstadt, Germany) 
Diethyl pyrocarbonate (DEPC) 97% Sigma-Aldrich (St. Louis, USA) 
Dithiothreitol (DTT) AppliChem (Darmstadt, Germany) 
DNase I  Roche (Mannheim, Germany) 
Dulbecco´s modified eagle medium 
(DMEM)  
PAN biotech ( Aidenbach, Germany) 
Dulbecco´s phosphate buffered saline 
(PBS) 
PAN biotech ( Aidenbach, Germany) 
Ethanol (absolute)  AppliChem (Darmstadt, Germany) 
Ethanol 70% 
Otto Fischar GmbH & Co. KG 
(Saarbrücken, Germany) 
Ethidium bromide AppliChem (Darmstadt, Germany) 
Ethylene diamine tetra-acetic acid (EDTA)  AppliChem (Darmstadt, Germany) 
Fetal calf serum (FCS) PAA (Pasching, Austria) 
Formaldehyde 37% Carl Roth (Karlsruhe, Germany) 
Hank´s balanced salt solution (HBSS) PAA (Pasching, Austria) 
Hydrochloric acid 37% Carl Roth (Karlsruhe, Germany) 
Isopropanol Carl Roth (Karlsruhe, Germany) 
Magnesium sulfate (MgSO4) Merck (Darmstadt, Germany) 
Maleic acid Merck (Darmstadt, Germany) 
Mercaptoethanol Sigma-Aldrich (St. Louis, USA) 
Nonidet P40 substitute (NP40)  Sigma-Aldrich (St. Louis, USA) 
O-Nitrophenyl β-D-galactopyranoside 
(ONPG) 
Sigma-Aldrich (St. Louis, USA) 
Pefablock SC Roche (Mannheim, Germany) 
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Potassium chloride (KCl) Merck (Darmstadt, Germany) 
Protein A  Agarose (PAA) Roche (Mannheim, Germany) 
Proteinase K, recombinant, PCR grade  Roche (Mannheim, Germany) 
μQuant Microplate spectrophotometer Bio-Tek (Winooski, USA) 
Roti®-Phenol Carl Roth (Karlsruhe, Germany) 
Sodium acetate Sigma-Aldrich (St. Louis, USA) 
Sodium carbonate, Na2CO3 Merck (Darmstadt, Germany) 
Sodium chloride Sigma-Aldrich (St. Louis, USA) 
Sodium dodecyl sulfate ultra-pure (SDS) Carl Roth (Karlsruhe, Germany) 
Sodium chloride Sigma-Aldrich (St. Louis, USA) 
Sodium hydrogen phosphate  
(Mono/Dihydrate) AppliChem 
(Darmstadt, Germany) 
Sodium hydroxide pellets  Merck (Darmstadt, Germany) 
Sodium phosphate  Sigma-Aldrich (St. Louis, USA) 
Trypsin-EDTA (10x) PAA (Pasching, Austria) 
Tris hydrochloride (Tris-HCl)  Carl Roth (Karlsruhe, Germany) 
Triton X-100  AppliChem (Darmstadt, Germany) 
Trypan blue  Sigma-Aldrich (St. Louis, USA) 
Tween 20 SigmaUltra  Sigma-Aldrich (St. Louis, USA) 
Ultra-pure Agarose Invitrogen (Paisley, UK) 
5.1.2 Kits  
Table 3: Kits 
DC Protein Assay  Bio-Rad (Hercules, USA) 
DIG High Prime DNA labelling and 
Detection Starter Kit II 
Roche (Mannheim, Germany) 
DIG RNA labelling Roche (Mannheim, Germany) 
MycoZap™ Plus-CL  Lonza (Cologne, Germany) 
PEG Virus Precipitation Kit Biovision (Milpitas, USA) 
QIAamp DNA Blood mini kit Qiagen (Hilden, Germany) 
QIAGEN Plasmid Maxi kit Qiagen (Hilden, Germany) 
QIAquick Gel Extraction Kit  Qiagen (Hilden, Germany) 
QIAquick PCR Purification Kit Qiagen (Hilden, Germany) 
RedTaq ready mix, PCR reaction Mix Sigma-Aldrich (St. Louis, USA) 
T7 RNA Polymerase Roche (Mannheim, Germany) 
5.1.3 Equipment 
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Table 4: Equipment 
Autoklav varioklav  Thermo Scientific (Waltham, USA) 
BioDocAnalyze (BDA) digital, Gel 
documentation system 
Biometra (Göttingen, Germany) 
Cellulose Acetate Membrane Syringe 
Filters 
Corning (Tewksbury, USA) 
CO2 incubator Thermo Scientific (Waltham, USA) 
Eppendorf Research Pipets  
10/20/100/200/1000 μl Eppendorf 
(Hamburg, Germany) 
Fujifilm Luminescent Image Analyzer SIEBC (Shanghai, China) 
LaminAir HB 2448 Labexchange (Burladingen, Germany) 
Microplate Spectrophotometer BioTek (Vermont, USA) 
MilliQ water purification system  Millipore (Schwalbach, Germany) 
Nylon membrane, positively charged Roche (Mannheim, Germany) 
Onyx 2000 incubator  Hermle (Wehingen, Germany) 
Phase contrast microscope Leica microsystems (Wetzlar, Germany) 
Shaker platform, hybridization oven Thermo Scientific (Waltham, USA) 
Sterile syringe filter Corning (Tewksbury, USA) 
Stratalinker® UV Crosslinker  Stratagen (Waldbronn, Germany) 
Table top centrifuge 1457R Eppendorf (Hamburg, Germany) 
T3000 Thermocycler  Biometra (Göttingen, Germany) 
Thermomixer compact Eppendorf (Hamburg, Germany) 
3730XL DNA Analyzer 
Applied Biosystems (Foster City, 
CA, USA) 
5.1.4 Consumables 
Table 5: Consumables 
Amersham Hyperfilm MP 
GE Healthcare Life Science (Freiburg, 
Germany) 
Cell culture plates (6 cm)  BD Falcon (Franklin Lakes, USA) 
Cell Scrapper SPL life science (Pocheon, Korea) 
Cryotube vials 1.0 ml  Nunc (Penfield, USA) 
Costar® 96-well plates for ELISA  Corning (Tewksbury, USA) 
Disposable serological pipette 5/10/25/50 
ml  
Corning (Tewksbury, USA) 
Filter Cap Cell Culture Flask (75 cm) 
Greiner Bio-One (Frickenhausen, 
Germany) 
Parafilm  Pechiney packaging 
Pipet tips TipOne (1-10/20-200/100-1000 
μl)  
StarLab (Hamburg, Germany) 
Safe-lock tubes (0.5 ml/1.5 ml/2 ml)  Eppendorf (Hamburg, Germany) 
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Semper Care nitrile examination gloves  SemperMed (Vienna, Austria) 
Syringe without needle 2/5/10/20 ml 
(disposable)  
Terumo (Eschborn, Germany) 
5.1.5 Buffers and solutions 
Table 6: Buffers and solutions 
Beta-galactosidase assay buffer 60 mM Na2HPO4, 2H2O 
39 mM NaH2PO4, H2O 
10 mM KCl 
1 mM MgSO4 
2 mM DTT 
1mg/ml ONPG 
Beta-galactosidase extraction buffer (5x) 125 mM Tris-HCl (pH 8.0) 
10 mM EDTA 
50% Glycerol 
5% Triton X-100 
1M DTT 
Beta-galactosidase lysis buffer Beta-galactosidase extraction buffer 
(5x) 
2 mM DTT 
H2O 
Beta-galactosidase reaction mix 1mg/ml ONPG 
10 mM DTT 
Beta-galactosidase assay buffer 
BES-buffered saline (BBS buffer 2x) 1.5 mM Na2HPO4 
0.28 M NaCl 
0.05 M BES 
Bovine serum albumin (BSA) Solution 
(30%) 
30 g BSA 
in 100 ml PBS 
DEPC water 0.1% DEPC 
in Aqua dest (autoclaved) 
Digoxigenin (DIG) labeling detection buffer 0.1 M Tris-HCl 
0.1 M NaCl (pH 9.5) 
DIG labeling and detection wash buffer 0.1 M Maleic acid 
0.15 M NaCl (pH 7.5) 
0.3% (v/v) Tween 20 
DNA denaturing solution 1.5 M NaCl 
0.5 M NaOH 
DNA neutralizing solution 1.5 M NaCl 
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0.5 M Tris-HCl (pH 7.2) 
1 mM EDTA 
EDTA stock solution 100 mM EDTA (pH 8.0) 
in Aqua dest 
Hybridization wash solution 1 2x SSC 
(low stringency buffer) 0.05 % SDS 
Hybridization wash solution 2 0.1x SSC 
(high stringency buffer) 0.1 % SDS 
Maleic acid buffer 0.1 M Maleic acid 
0.15 M NaCl 
NaOH (solid) to pH 7.5 
 MOPS buffer 10x 200 mM MOPS buffer 
50 mM Sodium Acetate 
20 mM EDTA 
NaOH to pH 7.0 
RNA loading buffer 250 µl 100 % deionized Formamid 
83 µl of 37 % Formaldehyde 
50 µl 10x MOPS 
10 µl 2.5 % Bromophenolblue 
57 µl DEPC-treated water 
saline-sodium citrate (SSC) buffer (20x) 3 M NaCl 
0.3 M Sodium Citrate (pH 7.0) 
TNE buffer 0.1 M NaCl 
10 mM Tris-HCl (pH 8.0) 
1 mM EDTA (pH 8.0) 
Tris pH 6.8/pH 8.8 1 M Tris 
in Aqua dest 
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5.1.6 PCR primers for HDV amplification 
All primers were synthesized by Eurofins MWG Operon (Ebersberg, Germany). 
Table 7: PCR primers for HDV amplification 
Target Primer’s name Sequence 
Partial HDAg A1, Outer fw TCGGTCAACCTCCTGAGTTC 
A2, Outer rev GGGGAGTCCAGCAGTCTC 
A3, Inner fw CTTGTTCTCGAGGGCCTTCC 
A4, Inner rev CGAGTCCAGCAGTCTCCTCT 
Hyper variable domain B1, Outer fw GGCCACCCACTGCTCGAG 
B2, Outer rev TGTTCGCTGAAGGGGTCCT 
B3, Inner fw CTCGACTCGGACCGGCTCAT 
B4, Inner rev CGCTGAAGGGGTCCTCTGGA 
Hyper variable domain C1, Outer fw AGCAGACAAATCACCTCCAGAGGA 
C2, Outer rev CGGTCCCCTCGGAATGTTG 
C3, Inner fw CACCTCCAGAGGACCCCTTC 
C4, Inner rev AGCGAGGAGGCTGGGACCAT 
Hyper variable and 
autocatalytic domain 
D1, Outer fw CCGAGAGGGGACGAGTGAGG 
D2, Outer rev TTCCTCTTCGGGTCGGCATG 
D3, Inner fw ACGAGTGAGGCTTATCCCGG 
D4, Inner rev GTCGGCATGGCATCTCCAC 
Autocatalytic domain and 
partial HDAg 
E1, Outer fw CCAGGTCGGACCGCGAGGAGG 
E2, Outer rev ACAAGGAGAGGCAGGATCACCGAC 
E3, Inner fw GATGCCATGCCGACCCGAAGAG 
E4, Inner rev GAAGGAAGGCCCTCAAGAACAAGA 
Hyper variable domain F1, Outer fw GCCAAGTTTGGAGGGCACTC 
F2, Outer rev TTCCCCGGGATAAGCCTCA 
F3, Inner fw AAGTTTGGAGGGCACTCCGG 
F4, Inner rev TCACTCTTCCCCTCTCGG 
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5.1.7 PCR Primers for HBV amplification 
All primers were synthesized by Eurofins MWG Operon (Ebersberg, Germany). 
Table 8: PCR Primers for HBV amplification 
Target Primer’s name Sequence 
HBV full genome HBV WA-L, fw ACTGTTCAAGCCTCCAAGCTGTGC 
HBV WA-R, rev AGCAAAAAGTTGCATGGTGCTGGT 
Precore, core and 
partial polymerase gene 
FA1-L, fw TTTCACCTCTGCCTAATCATCTC 
FA1-R, rev TCTTGTTCCCAAGAATATGGTG 
Partial polymerase, 
partial HBsAg 
FA2-L, fw GCGTCGCAGAAGATCTCAAT 
FA2-R, rev TTGAGAGAAGTCCACCACGAG 
Partial polymerase, 
partial HBsAg, Enh I 
FA3-L, fw CTGCTGGTGGCTCCAGTT 
FA3-R, rev GCCTTGTAAGTTGGCGAGAA 
Enh I, Partial 
polymerase, X protein, 
Enh II 
FA4-L, fw GTATTGGGGGCCAAGTCTGT 
FA4-R, rev AAAAAGTTGCATGGTGCTG 
Partial S-HBsAg SOF, Outer fw TCATCTTCCTCTTCATCCTGCTGC 
SOR, Outer rev CCCCCAATACCACATCATCC 
SIF, Inner fw TCATCTTCTTGTTGGTTCTTCTGG 
SIR, Inner rev GAACAAATGGCACTAGTAAACTGAGC 
Basal core promoter, 
precore and partial core 
genes 
COF, Outer fw CACTTCGCTTCACCTCTGCAC 
COR, Outer rev AGCCCCGTAAAGTTTCCCAC 
CIF, Inner fw GAGGCATACTTCAAAGACTG 
CIR, Inner rev AGTTTCCCACCTTATGAGTC 
5.1.8 PCR primers with T7 promoter  
For in vitro transcription of DIG labeled HDV-AG-RNA.  
All primers were synthesized by Eurofins MWG Operon (Ebersberg, Germany).  
* Underlined is T7 promoter sequence 
Table 9: PCR primers for in vitro transcription of DIG labeled HDV-AG-RNA 
Target 
Primer’s 
name 
Sequence 
HDV full 
genome 
A1+T7 TAATACGACTCACTATAGGGTCAACCTCCTGAG* 
E4 GAAGGAAGGCCCTCAAGAACAAGA 
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5.1.9 Antibodies 
Table 10: Antibodies 
Polyclonal Rabbit Anti-Hepatitis B Virus Core 
Antigen (HBcAg) 
Abcam, Ltd. (Cambridge, United 
Kingdom) 
Anti-Digoxigenin-Ap Roche (Mannheim, Germany) 
Mouse monoclonal Hep B pre-S1 antibody 
(AP1) 
Santa Cruz Biotechnology, (CA, 
USA) 
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5.2 Methods 
5.2.1 Serum samples 
71 serum samples from 49 Iranian patients with chronic HBV/HDV co-infection, 
who had been referred to the Tehran Hepatitis Center (THC), were included in this 
study. The THC physician team prepared a questionnaire and recorded available risk 
factors, virological, clinical, histological and serological data. Signed informed 
consent was obtained from all participants, and the Ethics Committee of the 
Baqiyatallah Research Center for Gastroenterology and Liver Diseases (Iran) as well 
as from the RWTH University-Hospital Aachen (Germany, reference number EK 
159/11) approved the study. All patients were tested positive for HBsAg and HDV-
IgG antibody and negative for HBeAg, hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV) antibodies.  
I performed HDV full genome PCR amplification for all serum samples. As HBV 
could only be detected and amplified in a subgroup of these HBV/HDV-infected 
patients, a case-control study was designed by matching each HDV infected patient 
with positive HBV-PCR results (case) to two HBV mono-infected individuals with 
amplified fragments (control) with respect to the age, sex and HBeAg status of the 
patients.  
5.2.2 HDV cDNA synthesis 
HDV RNA was extracted from sera of the patients by the QIAamp viral RNA 
mini kit (QIAgen). Reverse transcription of RNA to synthesize cDNA was performed 
separately for each segment using the Transcriptor First Strand cDNA Synthesis Kit 
Material and methods 
___________________________________________________________________ 
35 
 
(Roche). All the steps were conducted on ice if not stated otherwise. 5 μg of RNA 
was mixed with 2 μl of related outer reverse primer (10 μM, Table 7) and the reaction 
volume was adjusted to 13 μl with water. Samples were incubated at 90°C for 10 
minutes (min) to remove any secondary RNA structures. 7 μl of Reverse 
Transcription PCR Mix containing, nucleotides (2 μl, 10 mM each), reverse 
transcriptase (20 U/μl, 0.5 μl) and buffer (4 μl) were added and reverse transcription 
was performed according to the following protocol: 
Step 1 Start 25°C 10 min 
Step 2 RT reaction 50°C 60 min 
Step 3 Inactivation 85°C 5 min 
Step 4 Stop 4°C ∞ 
The cDNA solutions were diluted 3 times with water and stored at -20°C for further usage.  
5.2.3 HDV genome PCR and sequencing 
HDV whole genome amplification was performed by nested-PCR using specific 
primers for overlapping segments (Table 7). 3 μl of cDNA and specific outer primers 
(20 μM each) were added to 25 μl of the RedTaq ready PCR master mix (Sigma-
Aldrich) containing dNTPs and DNA polymerase for the first round of PCR. 5 μl of the 
first round PCR reactions and inner primers were used for 50 μl second round 
reaction mixes. PCR was performed on the T3000 Thermocycler (Biometra) under 
the following PCR protocol: 
Step   Temperature Time Cycle 
Step 1 denaturation 95°C 3 min 1 
Step 2 denaturation 95°C 1 min 35 
annealing 62°C 1 min 
Extension 72°C  1 min 
Step 3 Extension 72°C  10 min 1 
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Amplicons were purified using the QIAquick PCR purification kit (QIAgen) and 
subjected to bidirectional primer-walking sequencing using the 3730XL DNA Analyzer 
(Applied Biosystems).  
5.2.4 HBV genome PCR and sequencing 
HBV viral DNA was extracted from serum samples of the patients using 
QIAamp DNA blood mini kit (Qiagen) and subsequently subjected to PCR for 
rt/HBsAg/Enh I and Enh II/BOX β/BCP/PC amplifications. 5 μl of DNA dilution and 
specific primers (Table 8) added to the RedTaq ready PCR master mix (Sigma-
Aldrich) containing dNTPs and DNA polymerase. PCR was performed on the T3000 
Thermocycler (Biometra) under the following PCR protocol: 
Step   Temperature Time Cycle 
Step 1  denaturation 95°C 2 min & 30 S 1 
Step 2  denaturation 94°C 1 min 35 
annealing 55°C 1 min & 30 S 
extension 72°C  2 min 
Step 3 extension 72°C  10 min 1 
 
For the samples with low quality of PCR product, or un-successful PCR 
amplifications, nested-PCRs for HBsAg and HBcAg were conducted. HBsAg 
amplification was performed under the following protocol using Partial S-HBsAg 
primers (Table 8):    
Step   Temperature Time Cycle 
Step 1  denaturation 94°C 4 min  1 
Step 2  
denaturation 94°C 30 S 25 (first round) 
annealing 62°C 35 S 35 (second round) 
extension 72°C  30 S   
Step 3 extension 72°C  3 min 1 
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Basal core promoter, precore and partial core genes amplification was 
conducted using the primers listed in Table 8 and under the following protocol: 
Step   Temperature Time Cycle 
Step 1  denaturation 94°C 4 min  1 
Step 2  
denaturation 94°C 45 S 
35 annealing 
62°C (first round) 
55 S 
53°C (second round) 
extension 72°C  55 S 
Step 3 extension 72°C  3 min 1 
 
PCR products were purified using QIAquick PCR purification kit (Qiagen) and 
subjected to sequencing using the 3730XL DNA Analyzer (Applied Biosystems).   
5.2.5 HBV and HDV sequence analysis 
All sequences were edited manually and all the fragments were assembled 
using BioEdit sequence alignment editor, version 7.2.0 68. Alignment and genotyping 
of edited sequences were performed with MEGA software version 5.2 58. Sequences 
were then compared with consensus wild type reference genes regarding the 
genotype of the isolates for mutation analysis in amplified fragments. 
5.2.6 Evolutionary and phylogenetic analysis 
To perform the evolutionary and phylogenetic analysis, separate multiple 
sequence alignments were carried out for the HDV assembled full-length sequences 
as well as HDAg, HBsAg and rt fragment sequences using the MEGA software, 
version 5.2 69. Kimura 2-parameter algorithm was used to compute evolutionary 
distances using MEGA software 70. Phylogenetic relationships, and evolutionary rates 
were also calculated with the Neighbour-Joining (NJ) method using 1000 replicates 
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bootstrap value by MEGA software and confirmed by maximum likelihood analysis 
70,71. 
5.2.7 Selective pressure analysis 
The numbers of non-synonymous and synonymous substitutions per site (dN 
and dS, respectively) for each codon of HDAg (for HBV-HDV double-infected 
patients) and S-HBsAg (for HBV mono- and HBV/HDV double-infected patients, 
separately) were estimated to investigate the impact of selective pressure on these 
proteins. Studied cases were aligned based on their nucleotide sequences and 
applied for selection analysis by VarPlot software 
(http://sray.med.som.jhmi.edu/SCRoftware/VarPlot/). The Nei-Gojobori method was 
used for the dN/dS calculations. A dN/dS ratio of 1 is indicative of the same levels of 
synonymous and non-synonymous mutations at each position, which leads to the 
lack of selective pressure at these sites known as neutral evolution. The ratios higher 
than 1 (dN/dS > 1) indicate a fitness advantage of non-synonymous changes and 
therefore a positive selection and for those which are less than 1 (dN/dS < 1) a 
negative selection is expected due to the detrimental effect of non-synonymous 
mutations at those sites 72,73.   
5.2.8 Transfection of HBV and HDV constructs 
Replication-competent HBV 1.28 plasmid vectors (genotype A, subtype adw2) 
containing wild-type (WT) sequence and different mutations alone or in combination, 
including LAM-resistance (SM: rtM204I, DM: rtL180M+rtM204V), immune escape 
variants (sG145R, sP120T), PC (G1896A/C1858T) and BCP (A1762T/G1764A) 
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mutations, were generated as previously described 31,37. HDV pcDNA3.1-D2, 
containing two tandem repeats of HDV genotype 1 under the control of CMV 
promoter was provided by Dr. Farida Behzadian, Tarbiat Modares University, Tehran, 
Iran 74. The amount of transfected viral DNA was kept constant in all experiments 
(6.5 µg/6 cm dishes) by using pBluescript vector instead of HDV in mono-transfected 
plates. To control the transfection efficiency, 0.5 µg of pCMV beta-galactosidase 
(beta-Gal) vector was co-transfected in all experiments, and its enzymatic activity 
was measured from cell lysates 37. Series of HBV mono-transfections were also 
provided as controls along with double-transfection experiments. Human hepatoma 
cell line, HuH-7, was used as differentiated hepatocyte derived cellular carcinoma cell 
line for plasmid transfection. Confluent cell suspensions were seeded into 6 cm petri 
dishes with a density of 1.8 million cells/6 cm plate and fed by Dulbecco modified 
Eagle medium (DMEM, PAN biotech), supplied with 10% fetal bovine serum (PAN 
biotech) and Mycozap plus CL (Lonza) as antibacterial and antifungal element. After 
reaching 60-70% confluence, cells were transiently transfected with 1 µg-HDV and 5 
µg-HBV constructs by calcium phosphate DNA precipitation method. For each plate a 
total amount of 6.5 µg of transfection vectors were mixed with 150 µl of calcium 
chloride dehydrate (CaCl2)-0.25 M (Merck) and 150 µl of BES-buffered saline (BBS), 
2x and the mixtures were kept at room temperature for 20 min followed by adding the 
transfection solutions, drop by drop, to each plate (Figure 7). 
5.2.9 HBV progeny-DNA isolation  
To detect HBV progeny DNA for intracellular HBV replication evaluation, cells 
were collected (from two plates of each set of transfection experiments) and lysed 
seven days after transfection on ice using 900 µl of fresh lysis buffer including 15 ml 
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Progeny DNA Lysis Stock, 30 µl NP40 (Sigma), 15 µl Mercaptoethanol, 60 µl 
Pefablock-0.25 M (Roche) and 15 µl DTT-1 M (AppliChem), followed by lysis through 
metal beads vortex.  
  
Figure 7: Transfection of HBV and HDV constructs (experimental scheme) 
HuH-7 human hepatoma cells were seeded into 6-cm petri dishes with a density of 1.8 million cells/6 
cm plate and transiently transfected with 1 µg HDV and 5 µg HBV constructs by calcium phosphate 
DNA precipitation method. The amount of transfected viral DNA was kept constant in all experiments 
(6.5 µg/6 cm dish) by using pBluescript vector instead of HDV in mono-infected plates. A pCMV beta-
galactosidase (beta-Gal) vector was co-transfected in all experiments to control transfection efficiency. 
The medium was changed two times, and cells were harvested seven days after transfection for 
subsequent HBV-DNA, HBsAg, HBeAg, HDV-RNA and beta-Gal activity analysis. PBS: pBluescript, β-
gal: beta-galactosidase coding vector.  
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To exclude cell debris and nucleus from the cell lysates, samples were 
incubated with protein A-agarose (PAA, Roche). PAA solution was first washed three 
times with TNE buffer (1000g, 1 min) and 40 µl of the washed solution was mixed 
with cell lysates followed by incubation for 4 hours at 4°C on a rocking platform.  
After centrifugation (12,000 g for 5 min), and separating supernatants from 
precipitated cell debris, 12 µl of each supernatant was stored for protein assay and 2 
µg of rabbit polyclonal Anti-HBcAg antibody (ab115992, Abcam) was added to the 
rest. The mixtures were incubated for 1 hour at 4°C on a rocking platform. 40 µl of 
prewashed PAA was added to the suspensions and incubation continued overnight 
at 4°C on a rocking platform.  
Agarose-antibody-antigen complexes were precipitated by centrifugation 
(12,000 g for 10 min) and suspended in 500 µl TNE buffer. 
HBV nucleocapsid complexes were subjected to proteinase K (Roche)-sodium 
dodecyl sulfate (SDS, Carl Roth) digestion for separation of core proteins from DNA. 
150 µl of fresh proteinase K buffer (including: 1.84 ml TNE buffer, 100 µl 20%-SDS 
and 66 µl proteinase K) were added to resuspended pellets. Samples were incubated 
for 2 hours at 56°C in a shaker thermo block (1400 rpm). After incubation, 200 µl 
phenol-chloroform (Carl Roth) was added to each sample followed by mixing for 10 
min at room temperature in the shaker block and 15 min full speed centrifugation at 
room temperature.  
Supernatants were transferred to new tubes, mixed with 2.5x absolute-ethanol 
(Applichem) and 0.1x Sodium Acetat (3 M, pH: 4.6, Sigma-Aldrich) and incubated 
overnight at -80°C for DNA precipitation. After two times washing with 500 µl 70%-
ethanol (Fischar), HBV-DNA was precipitated by 15 min full speed centrifugation at 
4°C and dissolved in 50 µl distilled water. 
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5.2.10  HBV DNA isolation from cell culture supernatants  
Cell culture supernatants were collected and centrifuged at 16,000 g for 15 min 
at 4°C to remove cell debris. 400 µl-PEG was added to 2 ml of supernatants and the 
mixtures were incubated overnight at 4°C on a rocking platform. After centrifugation 
at 16,000 g for 30 min at 4°C, viral pellets were re-suspended in TNE buffer (100 µl) 
and subjected to proteinase K–SDS digestion, phenol-chloroform DNA extraction and 
ethanol-DNA precipitation as mentioned for HBV progeny-DNA extraction. 
5.2.11 HBV DNA southern blot analysis 
The random primed Digoxigenin (DIG)-labeled HBV-DNA probe was prepared 
from a full length HBV DNA obtained through agarose gel extraction of a full genome 
HBV PCR product. Double distilled water was added to 1 µg purified DNA to the 
volume of 16 µl, the solution was denatured at 90°C for 10 min and quickly chilled on 
ice. 4 µl of DIG-High Prime solution (Roche) was added to the denatured DNA and 
the mixture was incubated overnight at 37°C.   
Isolated HBV-DNAs from transfection experiments (25 µl) were transferred to 
positively charged nylon membranes (Roche) after running on 1% agarose gel via an 
overnight capillary transfer method. 
Membranes were pre-hybridized with hybridization solution (Roche) and 
continuous shaking for 30 min at 42°C. The pre-hybridization buffer was replaced 
with a pre-warmed mixture of random primed DIG-labeled HBV DNA probe (25 ng 
per ml of hybridization buffer, Roche) and hybridization buffer and incubation 
continued overnight at 42°C. 
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Membranes were washed two times with the low stringency wash buffer 
(Hybridization wash solution 1) and incubated at room temperature with blocking 
solution for 30 min followed by Anti-Digoxigenin-Ap (Roche) incubation at room 
temperature for 30 min and, washing and detection with CSPD solution (Roche). For 
luminescent reaction detection, membranes were exposed to Fujifilm Luminescent 
Image Analyzer. 
5.2.12 HBV protein measurement in supernatant 
HBsAg and HBeAg levels were measured in the supernatants by commercially 
available kits for ELISA (Modular Analytics E170, Roche). The values were 
normalized to the beta-Gal transfection efficiency. 
5.2.13 HBV protein assay 
Total protein concentration of the lysed cells was determined using Bio-Rad 
protein assay to be applied for normalization of progeny-DNA measurements. 2 µl of 
each cell lysate was diluted in 800 µl distilled water and mixed with 200 µl Bio-Rad 
dye reagent concentrate. Samples were incubated at room temperature for 30 min 
and absorbance was measured using Spectrophotometer at 595 nm along with 
Bovine serum albumin (BSA) dilutions (1.2 to 10.0 µg/ml) as standard reactions.     
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5.2.14 Beta-Gal assay 
Beta-Gal assay has been used by many investigators as a standard control 
assay for transfection efficiency evaluation. I used one plate (out of four plates) from 
each set of transfection assays to analyze beta-Gal activity in each set of 
experiments (Figure 7). 
Cells were washed with phosphate buffered saline (PBS, PAN biotech) and 
detached from the plates by adding 350 µl of beta-Gal lysis buffer and incubation of 
the plates in room temperature for 10 min. Detached cells were transferred into the 
pre-cooled Eppendorf tubes (Eppendorf), lysed by vortexing and centrifuged at full 
speed for 30 min at 4°C. 
10 µl of the cytosolic phase was transferred into the ELISA plate and 100µl 
beta-Gal reaction mix was added to it. Reactions were stopped by adding 50 µl of 1 
M Sodium Carbonate (Na2CO3, Merck) to each well of the ELISA plate. The optical 
densities were measured at 420- and 550-nm, 15 and 30 min after stopping the 
reactions. Resulted values were used for HBV-DNA, HDV-RNA, HBsAg and HBeAg 
measurements’ normalization.  
5.2.15 HDV RNA extraction 
Two plates from each set of transfection experiments were used for the 
measurement of HDV replication inside the cells and HDV virion release in the cell 
culture supernatant. One week after transfection, cells of two plates were poured in 
one tube and total RNA was isolated with the RNeasy kit (Qiagen).  
Viral particles from the supernatant of transfected cells (2 ml) were 
immunoprecipitated using mouse monoclonal antibody against HBV preS1 protein 
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(sc-57761; Santa Cruz Biotechnology) and protein-A agarose beads as explained for 
HBV progeny-DNA immune precipitation. Viral RNA was subsequently extracted 
using QIAamp viral RNA mini kit (Qiagen).  
5.2.16 HDV RNA Northern blot analysis 
HDV RNA with anti-genomic polarity was transcribed in vitro using T7 RNA 
polymerase kit (Roche) from a full-length HDV genome PCR product containing T7 
promoter as a template and labeled by DIG RNA labeling kit (Roche) to be used as 
detection probe. 1 µg template DNA (full length HDV purified PCR product) was 
added to a master mix containing ATP, GTP, CTP and DIG-labeled UTP (1 mM 
each) together with T7 RNA-polymerase (Roche) and incubated at 37°C for 2 hours.  
RNA samples were mixed with RNA loading buffer, boiled for 10 min at 65°C 
and run on a 1.2% formaldehyde gel in 1X 3-(N-morpholino) propanesulfonic acid 
(MOPS). After running, gels were stained with Ethidium Bromide (Applichem) for 
ribosomal RNA detection (to be applied for HDV cellular RNA measurements’ 
normalization) followed by RNA transfer to a nylon membrane via capillary transfer 
method overnight. 
 Membrane was pre-hybridized at 59°C for 30 min and labeled with DIG-labeled 
HDV probe (60 ng per ml of hybridization solution) overnight at the same 
temperature. Washing steps were performed using normal and high stringency 
washing buffers at room temperature and 68°C, respectively. Following procedures 
including adding antibody, washing steps and luminescent reaction detection were 
same as Southern blot assay.   
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5.2.17 Southern and Northern blot data quantification 
Quantification of data was done with ImageJ software 75 and results were 
normalized to ribosomal RNA (rRNA) content of the cell lysate (for HDV cellular 
RNA), to total protein of the cells (for HBV progeny-DNA) and to beta-Gal transfection 
efficiency (for intra and extracellular values). 
5.2.18 Statistics 
Statistical analysis of clinical data was performed using IBM SPSS version 21.0 
(IBM Corp., Armonk, NY, 2012). Statistical analyses from the in vitro experimental 
data were conducted using GraphPad Prism (GraphPad Software, San Diego 
California USA). Experimental results are reported as mean ± standard deviation. 
One-way ANOVA with Bonferroni post-test was applied for comparisons between the 
groups; a P-value of <0.05 was considered statistically significant.  
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6 Results 
6.1 Phylogenetic analysis of full-length HDV and L-HDAg isolates revealed a 
single genotype, close ancestry and limited genetic diversity  
71 serum samples from patients with chronic HBV infection, who were attending 
the clinic regularly and were HBsAg positive (more than 6 months), HBeAg negative 
and anti-HDAg (IgG) positive, were included in this study. Patients were either 
receiving no treatment or IFN (for one year), LAM and ADV, alone or in combination 
(continued based on the serological condition and virological response of the 
patient). 
Among the enrolled samples, five were negative by PCR analysis, and 22 
samples could be amplified for only small portions of the HDV genome, so that these 
cases were excluded from the analysis. Thus, 34 patients were available for the 
cross-sectional study cohort. Demographic, clinical, serological, virological and 
biochemical data of these patients are shown in Table 11. The mean age of the 
patients was 42 years (ranging from 12 to 67 years), and 73.5% of the participants 
were male. Among all the patients, 64.7% were diagnosed with liver cirrhosis. 
Progression to cirrhosis was defined by liver histology and clinical parameters 
including platelet count <100,000 per mm³, features of surface nodularity by 
ultrasound, splenomegaly, prolonged prothrombin time (PT), ascites and/or 
esophageal varices by upper gastrointestinal endoscopy.  
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Table 11: Demographic and clinical data of HBV/HDV infected patients  
 (Note: ALT upper normal limit = 49 IU/L). F: female; M: male; ND: not determined; LAM: Lamivudine; 
ADV: Adefovir; IFN: Interferon  
Sample 
Sex Age 
ALT Disease HBV 
Risk Factor(s) Treatment 
Code (IU/L) Status 
Viral load 
(copies/ml) 
D1 F 27 56 Chronic Undetectable Family case, Tattoo LAM 
D2-A M 67 131 Cirrhosis Undetectable Sexual contact, Travelling abroad LAM +ADV 
D5-A F 40 53 Cirrhosis 3.1x10
5
 Family case LAM 
D7-A M 20 62 Chronic Undetectable Family case IFN 
D8 F 30 96 Cirrhosis Undetectable Family case No treatment 
D9-A M 55 55 Cirrhosis Undetectable Family case IFN 
D10-A F 49 69 Cirrhosis 1.1x10
3
 Family case ADV 
D13 M 57 51 Cirrhosis 4.7x10
5
 Experimental dentist LAM +ADV 
D15 M 34 34 Chronic 5.9x10
5
 Shared razor in prison, Sexual contact LAM 
D17 F 46 86 Cirrhosis 2.9x10
4
 Family case LAM 
D18 M 47 76 Cirrhosis Undetectable Warfield injury, Blood transfusion, 
Dental surgery 
LAM +ADV 
D21 F 45 95 Cirrhosis Undetectable Family case No treatment 
D23 M 63 65 Cirrhosis 3.7x10
4
 Blood transfusion IFN 
D24 M ND ND ND N/D ND ND 
D26 M 41 46 Chronic Undetectable Surgery IFN 
D27 M 33 92 Chronic Undetectable Family case, Dental surgery, 
Hospitalization 
No treatment 
D28 M 40 54 Cirrhosis Undetectable Family case, Tattoo No treatment 
D29 M 28 82 Cirrhosis Undetectable Family case, Dental surgery No treatment 
D32 M 47 73 Cirrhosis Undetectable Family case No treatment 
D33 M 36 ND Chronic N/D ND ND 
D34 M 52 77 Cirrhosis 5.9x10
5
 Family case IFN 
D37-A M 50 42 Chronic Undetectable Family case No treatment 
D39-A M 12 68 Chronic Undetectable Family case LAM 
D43 M 44 90 Cirrhosis Undetectable Family case LAM 
D49 M 51 156 Cirrhosis 5.0x10
3
 Family case No treatment 
D51 M 48 80 Chronic Undetectable Family case, Dental surgery No treatment 
D52 M 36 71 Chronic Undetectable Family case, Dental surgery LAM 
D55 F 51 63 Cirrhosis Undetectable Family case No treatment 
D58 M 56 104 Cirrhosis Undetectable Blood transfusion LAM 
D60 F 46 110 Cirrhosis Undetectable Family case No treatment 
D64 M 39 82 Cirrhosis Undetectable Major surgery IFN+ LAM 
D66 M 24 222 Chronic Undetectable Intravenous drug user, Imprisoned No treatment 
D69 M 44 67 Cirrhosis 2.34x10
4
 Family case IFN 
D70 F 41 21 Cirrhosis 1.08x10
2
 Family case IFN 
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Consensus sequences of the full-length HDV genome were obtained from 38 
samples following primer-walking and sequencing of purified PCR products from six 
overlapping segments. For additional six samples, consensus sequence information 
of the encoding L-HDAg region was determined. The full-length HDV isolates ranged 
from 1672 to 1682 nucleotides. Phylogenetic analyses of the 38 HDV full-length 
genome sequences (Figure 8A) as well as the 44 L-HDAg nucleotide samples 
(Figure 8B) revealed that the Iranian HDV isolates clustered with reference 
sequences of genotype 1 of HDV.  
 
Figure 8: Phylogenetic analysis of Iranian HDV isolates 
Phylogenetic analysis of Iranian HDV isolates based on full genome (A) and L-HDAg (B) sequences. 
Colors represent geographic distribution of the samples of our study, which were collected from 
different areas of the country. Bootstrap values above 70% are indicated at the branch nodes. 
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6.2 High rate of single amino acid mutations along with positive selection of 
mutations at immunogenic epitopes of L-HDAg 
I next performed a L-HDAg amino acid sequence alignment of all 44 isolates as 
well as a synonymous and non-synonymous mutation analysis of the L-HDAg 
nucleotides, in which dN/dS>1 indicated an overabundance of non-synonymous 
substitutions at each site (Figure 9). No deletions or insertions were observed among 
the sequences. Although HDAg protein bears more amino acid changes compared to 
structural proteins of other RNA viruses 76, functionally important amino acid 
positions such as Leu115, which has been shown to be necessary for in vitro RNA 
binding activity and viral replication 77, showed no variability.  
Different RNA binding domains have been suggested for HDAg, which were all 
Arginine-rich motifs. Nevertheless, Lys-Arg substitutions occurred regularly in the 
isolates from Iranian patients. All residues at the PTM sites were also conserved 
except for two substitutions, one Serine to Glycine exchange at position 2 in the D69 
isolate and one Arginine to Lysine switch at position 13 in the D1 isolate. However, in 
both cases the superseded residue has the same characteristics as the main one, 
thus the role of the amino acids might not be impeded by these replacements. There 
are also some features of heterogeneity in the packaging signal region including 
residues 198 and 202, as defined based on previously reported sequences from 
other countries 48,78, whose potential implications require further functional analyses. 
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Figure 9: L-HDAg amino acid sequence analysis 
 (A) L-HDAg sequence alignment logo based on 44 isolates from HBV/HDV co-infected patients. 
Functional domains (presented by boxes) and post-transcriptional modification sites (illustrated as 
circles) are indicated. (B) Sites under positive selection in L-HDAg of 44 isolates. A value of dN/dS>1 
indicates overabundance of non-synonymous mutations at each codon. The highlighted zone depicts 
the codons, which are affected by positive selection (codons 136 to 159). Boxes on top of the figure 
show the immunogenic epitopes of the protein. The alteration of amino acids at immunogenic CD8+ T-
cell and B-cell epitopes is noteworthy. RBD: RNA binding domain; CCD: coiled coil domain; NLS: 
nuclear localization signal; P: Phosphorylation; M: Methylation; A: Acetylation; I: Isoprenylation. BCE: 
B cell epitope, CD8+: CD8+ T-cell epitope, CD4+: CD4+ T-cell epitope 
79
.  
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Moreover, based on the substitution analysis, on average 10.6 % of L-HDAg 
codons (23 codon sites) were under positive selection, which was higher than 
previously reported rates for non-synonymous changes in the HDAg protein 73,80. 
Interestingly, the positively selected codons were located in CD8+ T-cell and 
immunodominant B-cell epitopes, related to cellular or humoral antiviral immune 
responses, respectively (Figure 9) 13,73. 
6.3 Remarkable differences in HBs and rt sequences between HBV/HDV and 
HBV-mono-infected individuals 
Of 71 HBV/HDV infected patients enrolled in this study, 24 cases (34%) had 
detectable HBV replication as assessed by positive real time PCR for HBV-DNA from 
serum. HBV amplification and sequencing of rt/HBsAg and Enh I resulted in 17 (71%) 
reliably amplified fragments. For Enh II, Box β and BCP domains 10 (41%) 
sequences were obtained and PC domain amplification resulted in only 7 (29%) 
fragments. Of note, the HBV/HDV infected patients with amplified HBV domains did 
not significantly differ with respect to sex, age, cirrhosis or serum ALT levels from the 
HBV/HDV-infected patients with un-detectable HBV (Table 12).  
  
HDV / amplified HBV HDV / not-amplified HBV 
p-value 
Infected patients Infected patients 
Number of patients 24 47 0.006 
Female (%)/ Male (%) 10 (41.6%) / 14 (58.4%) 16 (34.0%) / 31 (66.0%) - 
Age 41 (18 to 63) 42 (12 to 69) 0.763 
Cirrhosis 62.50% 73.00% 0.344 
ALT (U/L) 57.6 (20 to 86) 78.6 (19 to 154) 0.111 
Table 12: General data of the HBV/HDV infected patients with and without amplified HBV 
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For each case with amplified HBV in HBV/HDV infected patients, two HBV-
mono-infected patients with matched characteristics were studied as a control (Table 
13). The cases were matched for sex, age and HBeAg status, but HBV/HDV infected 
patients were more frequently diagnosed with cirrhosis, while their HBV-DNA levels 
were lower than those for HBV mono-infected individuals (Table 13), in line with 
expectations from the literature 44.  
 
  
HBV HBV/HDV 
p-value 
control group case group 
Total patients n.a. 71 n.a. 
Enrolled patients 34 17 n.a. 
Female (%) / Male (%) 
14 (41.1%) / 20 
(58.8%) 
7 (41.1%) / 10 (58.8%) 0.017 
Age  37.41 (17 to 54) 38.52 (18 to 58) 0.757 
Cirrhosis 14.70% 52.90% <0.001 
ALT (U/L) 62.5 (21 to 172) 56.14 (20 to 86) 0.928 
HBV viral load (copies/ml) 4.0 x10
7
 3.4 x10
4
 <0.001 
Table 13: General data of the HBV/HDV infected patients with active HBV replication and the HBV 
mono-infected control group 
 
Genotype analysis of the samples based on HBs and rt nucleotides, revealed 
that all the isolates (mono- and double-infected patients) belong to HBV genotype D 
(Figure 10).  
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Figure 10: HBV phylogenetic analysis  
Sequence analysis of HBV domains containing the entire S and partial rt nucleotides, revealed that all 
of the isolates from HBV-mono (black) and HBV/HDV double-infected (red) patients belong to 
genotype D. HBV sequence analysis based on HBs nucleotides (A) and rt nucleotides (B). GT: 
genotype. 
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The number of non-synonymous and synonymous substitutions per site (dN/dS) for 
each codon of HBsAg and the rt domain were calculated for HBV/HDV- and HBV-
mono-infected patients (Figure 11 A, B), and sites with an increased dN/dS ratio were 
considered indicative of ongoing positive selection at these regions. As shown in 
Figure 11 A, selective pressure was noted at S-HBsAg residues 25 to 70 for the case 
group and at 180 to 205 for case and control groups. Both cytosolic domains (CYL-I 
and II) of S-HBsAg are located at these regions 81.  
 
Figure 11: HBs and RT protein alterations in HBV/HDV infected patients 
Comparison of HBV amino acid changes between HBV mono-infected (control, black) and HBV/HDV 
double infected (case, red) patients. Amino acid substitution rates (dN/dS) for the S-HBsAg (A) and 
the RT domain (B).  
 
The increased dN/dS ratio for the RT region occurred at residues 25 to 145 for 
the case group and 100 to 145 for the control group (high-lighted zone, Figure 11 B). 
There was also an increase for both groups at residues 190 to 230. The A, G, F and 
C functional domains of RT are located at the regions under positive selection. The F 
and G boxes (also known as RT-1) are suggested to be involved in RNA priming and 
packaging 82, while box A is involved in dNTP versus NTP discrimination 83. The RT-
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C domain, at which most of drug resistance mutations occur, overlaps with the CYL-II 
in the C-terminal region of the S-HBsAg.  
6.4 Reduced frequency of PC and BCP mutations in HBV/HDV infected 
patients 
I further analysed the sequences for distinct mutations conferring resistance to 
LAM, HBsAg immune escape variants as well as mutations in Enh I and II, Box β, PC 
and BCP domains. Nine cases of the 17-HBV/HDV infected sequences (53%) 
showed rtM204I mutation, of which one patient harbored a simultaneous sP120T 
immune escape mutation. Three cases of LAM resistance (one rtM204I and two 
rtL180M+rtM204V) occurred in the HBV-mono-infected cohort.  
Strikingly, a large proportion of HBV-mono-infected patients had 
A1762T/G1764A (40.0%) and G1896A (35.7%) mutations in their BCP and PC 
domains, respectively (Figure 12A). Although the frequency of PC mutations was 
similar between HBV-mono and HBV/HDV-double infected patients but on the 
contrary, A1762T/G1764A-BCP mutations occurred at very low frequency (10.0%) in 
the HBV/HDV-double infected group. The A1131G and A1167T mutations occurred 
exclusively in Enh I nucleotide domain of HBV/HDV-double infected cases (35.2% 
and 41.0%, respectively). I observed a low frequency of mutations (less than 10%) in 
either of the groups in Enh II and BOX β (Figure 12 B).  
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Figure 12: Nucleotide mutations at HBV enhancer domains and transcription controlling elements of 
the patients.  
The nucleotide mutations at HBV-BCP (A1762T/G1764A) and PC (G1896A) domains are shown (A) 
and frequency of these mutations as well as mutations in Enh I, II and Box β are compared between 
HBV-mono (dark blue) and HBV/HDV-double (light blue) infected patients (B). 
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6.5 No functional impact of HDV co-transfection on the replication of HBV 
polymerase or immune escape mutants  
The striking differences in the HBsAg cytosolic domains and the frequency of 
BCP mutations between HBV/HDV- and HBV-mono-infected patients strongly 
indicated that HDV co-infection may affect functional properties of HBV mutants. I 
therefore comprehensively analysed the impact of HDV co-infection on HBV 
replication in vitro. To this end, replication-competent HBV vectors with defined 
mutations were transiently transfected in human hepatoma cells, either alone or 
together with HDV-expressing plasmids. The extracellular levels of HBsAg, but not 
HBeAg, were dramatically reduced in constructs containing sG145R or sP120T 
immune escape variants, independent of concomitant HDV infection (Figure 13 A-B). 
In agreement with our previous reports 31, polymerase mutations conferring LAM 
resistance as well as combination of polymerase with immune escape mutations 
impaired HBV replication in vitro, as evidenced by intracellular levels of HBV progeny 
DNA (Figure 13 C) as well as the levels of extracellular HBV virions released into the 
supernatant of transfected cells (Figure 13 D). Interestingly, co-infection with HDV 
slightly reduced virion release of LAM-resistant mutants in vitro, but had overall no 
major impact on the replication of HBV polymerase or immune escape mutants 
(Figure 13 C-D). 
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Figure 13: Functional impact of HDV co-transfection on replication of HBV polymerase and surface 
mutants 
Huh7 hepatoma cells were transiently transfected with replication-competent HBV plasmids. 
Compared to mono-transfection (S=single, dark gray), the effect of co-transfection with HDV 
(D=double, light gray) on HBV replication was studied. HBsAg (A) and HBeAg (B) levels in the 
supernatant, intracellular HBV progeny DNA levels (C, representative Southern Blot after 
immunoprecipitation for anti-HBc and statistics) and released HBV virions (D, representative Southern 
Blot and statistics) are shown. Results from n≥3 independent experiments with n=2 biological 
duplicates each. RC: relaxed circular form (4.0kb), DL: double-stranded linear form (3.2kb), SS: HBV 
DNA full-length single-stranded form (1.5kb).  
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6.6 HBV replication of PC or BCP mutants is highly impaired in HBV/HDV co-
transfected cells  
PC or BCP mutations strongly reduce HBeAg release (Figure 14 A-B) and are 
therefore commonly associated with HBeAg-negative hepatitis B 24. On a molecular 
level, PC and especially BCP can enhance the replication of HBV, e.g., the 
replication of LAM-resistant mutants 37. In fact, I observed increased HBV replication, 
particularly high intracellular HBV progeny DNA levels (Figure 14 C) and preserved 
extracellular HBV virions (Figure 14 D), in BCP-containing mutants in vitro. On the 
contrary, co-transfection of HBV mutants with HDV strongly reduced the replication of 
PC- or BCP-carrying HBV constructs (Figure 14 C-D). These data suggest a strong 
inhibitory effect of HDV on HBV PC/BCP mutants and are in agreement with the 
sequence analyses from the patient cohort, where BCP mutations were less frequent 
in HBV/HDV-double infected cases compared to HBV- mono infected patients (Figure 
12). 
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Figure 14: Functional impact of HDV co-transfection on replication of HBV PC or BCP containing 
mutants  
HuH-7 hepatoma cells were transiently transfected with replication-competent HBV plasmids 
containing different mutations in conjunction with PC or BCP mutations. Compared to mono-
transfection (S=single, dark grey), the effect of co-transfection with HDV (D=double, light grey) on HBV 
replication was studied. HBsAg (A) and HBeAg (B) levels in the supernatant, intracellular HBV 
progeny DNA levels (C, representative Southern Blot after immunoprecipitation for anti-HBc and 
statistics) and released HBV virions (D, representative Southern Blot and statistics) are shown. 
Results from n≥3 independent experiments with n=2 biological duplicates each. RC: relaxed circular 
form (4.0kb), DL: double-stranded linear form (3.2kb), SS: HBV DNA full-length single-stranded form 
(1.5kb). 
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6.7  HBV polymerase and HBsAg mutations affect intracellular replication 
and extracellular release of HDV upon co-transfection in vitro 
I next analysed whether different mutations in the HBV genome influenced 
replication and/or secretion of HDV in vitro. Interestingly, HDV replication was 
significantly affected by mutations in the HBV polymerase and HBsAg region.  
Intracellular HDV RNA levels were significantly reduced in cells co-transfected 
with HDV and sG145R or sP120T HBV mutants in conjunction with LAM resistance 
(Figure 15 A). However, these mutants were associated with increased levels of 
secreted (extracellular) HDV RNA (Figure 15 B).  
On the other hand, polymerase mutations conferring LAM resistance showed 
preserved intracellular HDV RNA upon co-transfection with HDV (Figure 15 A), but 
reduced HDV secretion (Figure 15 B). These data indicate that HDV replication and 
secretion is strongly influenced by mutations in the HBV polymerase and/or HBsAg. 
Notably, PC or BCP mutations did not further impact HDV replication or secretion in 
vitro (Figure 15 A.B). Overall, these analyses support the concept of direct 
interactions between HBV and HDV viruses within double-infected hepatocytes 12 
and may provide a functional basis to explain the impact of HDV co-/super-infection 
on the HBV genome. 
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Figure 15: Functional impact of mutations in the HBV genome on HDV replication 
HuH-77 hepatoma cells were transiently transfected with HDV-expressing and replication-competent 
HBV plasmids containing different mutations. Intracellular HDV G-RNA levels (A) and extracellular 
HDV RNA levels in the supernatant (B) of co-transfected cells were assessed by Northern Blot. 
Results from n≥3 independent experiments with n=2 biological duplicates each. 
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7 Discussion 
Globally about 350 to 400 million people are infected with HBV. Of this number, 
about 15 million patients are infected with delta hepatitis. HDV infection occurs in the 
presence of HBV in form of co- or super-infection 1. Delta hepatitis is especially 
relevant in immigrants from endemic areas including Middle East, Asia or Southern 
Europe. Double infection with HBV and HDV commonly leads to rapid progression of 
liver fibrosis, cirrhosis and increased risk of HCC 1. Therefore, understanding 
molecular interactions between both viruses and implications of mutations on HBV or 
HDV replication may allow to better control damaging processes related to viral 
hepatitis and help to develop new therapeutic strategies for viral eradication 84. 
7.1 HDV and HBV genotypes in HBV mono- and HBV/HDV double-infected 
patients 
Based on the phylogenetic analysis of our HDV sequences, all the HDV isolates 
positioned together with reported HDV genotype 1 from East Asia (Taiwan, China), 
the Middle East (Iran, Turkey), Europe (Italy) and US, but separated from HDV 
genotype 1 isolates proposed as the “African-Middle East” subgroup that has been 
introduced in 1996 85. Phylogenetic sequence analysis of HBV isolates based on HBs 
and rt domains also revealed that, in agreement with previous reports from Iran, all 
the sequences belong to genotype D 17. 
Although an association between HDV-1/HBV-A and -D and HDV-3/HBV-F and 
-A has been observed, independent investigations suggest that the HBV/HDV co-
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infections are mainly representative of common genotypes of each of the viruses in 
certain geographical areas and not specific for distinct HBV or HDV genotypes 44. 
Moreover, studies have shown that, despite of non-homogenous distribution of 
different HDV genotypes in the world, there is no limitation, at least for HDV 
genotype-1, to be accompanied by different genotypes of HBV for infection and 
replication. However, there are some differences between HBV genotypes to support 
HDV infection, thus serum-ALT levels and the degree of liver inflammation may vary 
between different co-infections based on the concomitant HBV genotype. 
Accordingly, a D-genotype HBsAg supports HDV infectivity more effectively than B, E 
or A-genotypes 86. Furthermore, it is not only the HBV genotype that affects HDV 
replication or infectivity but also the quantitative availability of HBsAg. In this regard, 
a significant role has been attributed to the HBsAg levels than to HBV genotypes for 
HDV assembly 87.  
7.2 HDAg mutational pattern and conserved domains 
 A relatively high variability in the amino acid composition of the HDAg protein is 
a common feature in HDV 76, due to the lack of proofreading activity for cellular RNA 
polymerases I and II, which are responsible for HDV RNA replication 1,88. The clinical 
emergence of defective isolates with deletions or insertions in HDAg leading to a 
frame shift or early stop codon have also been reported, but at a very low frequency 
compared to wild type HDV isolates 88. The sequence analysis revealed that most of 
the HDAg-PTM sites are well conserved among all the studied isolates. However, it is 
important to note that the methodology of this study may not be capable of detecting 
minor viral subspecies that occur at very low frequencies, and further studies may be 
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conducted to confirm our results by additional measures such as deep sequencing 
from serum as well as infected liver tissue.  
The 19 amino acid extension at the C-terminal domain of L-HDAg, which is 
responsible to interact with HBsAg for HDV RNP complex packaging, contains the 
CXXX motif, a PTM site that mediates farnesylation of L-HDAg at C211 and results in 
a higher hydrophobicity at this domain 1. The C211-farnesylation is essential for 
interaction with HBsAg in the process of HDV packaging and has been recently used 
as a target for antiviral candidates which are in their early clinical trials against HDV 
infection 89. In our analysis, C211 was conserved among all the sequences (Figure 
9). The hydrophobic amino acids at the C-terminal domain of L-HDAg are also shown 
to play a critical role in HDV packaging. Indeed the difference in packaging efficiency, 
virion release and disease outcome, which has been observed for different 
genotypes of HDV, is mainly due to the high divergence of L-HDAg C-terminal 
domain among the genotypes 90. Regarding the importance of hydrophobic residues 
in C-terminal domain of L-HDAg for HDV packaging, the A202S substitution which 
has happened in about 77% of the isolates may induce unknown effects on HDV 
packaging. 
In our analysis not only the C-terminal domain PTM motif, but also the target 
residues for modifications distributed all over the HDAg were mostly conserved. 
These modifications include S2, 123 and 177 phosphorylation (to interact with RNA 
polymerase II and mediate RNA binding), R13 methylation (to induce HDV 
replication) and K72 acetylation (for HDV accurate localization and replication) 91,92. I 
observed one S2G and one R13L exchange in two different isolates. However, in 
both cases the superseded residue has the same characteristics as the main one, 
thus the role of the amino acids might not be impeded by these replacements.  
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The N-terminal domain of L-HDAg, which shows the highest variability 
compared to other domains in our study, is responsible for transactivation of HDV 
RNA replication as well as HDAg oligomerization. The effect of amino acid 
substitutions in this domain has been investigated in previous studies, and no 
particular pattern could be deduced from the amino acid variations 93,94. It seems that, 
where possible, HDV adopts different amino acid substitutions in this domain to 
promote S-HDAg oligomerization and sustain its RNA replication through activation of 
various intermediate complexes 93. In general, although HDAg harbors a high rate of 
mutations compared to the structural proteins of other RNA viruses such as 
influenza, hepatitis C virus or retroviruses 95, the critical residues which are involved 
in HDV RNA replication, RNA binding and virion packaging are highly conserved 
among the isolates. The effects of amino acid substitutions especially in coiled coil 
domain (CCD) or the A202S in packaging signal, however, require further 
investigations. 
7.3 Effects of selective forces on L-HDAg and S protein mutations and role 
of these mutations on viral replication  
The quasispecies nature of the viruses provides the opportunity for them to 
replicate more efficiently in a preventive condition or to escape immune responses 
due to some of the genomic mutations. Positive selection forces, such as immune 
responses in the host or competition for limited resources, may determine sequence 
diversity and the mutational pattern 96,97.  
Results obtained from other studies indicated that the rates of non-synonymous 
substitutions in HDV is higher compared to other RNA viruses, because the third 
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position of the codons is more conserved in this virus 76,95,98. In a previous study on 
33 HDAg sequences of genotypes 1 to 4, eighteen codons were detected to be under 
positive selection 80 and in a follow up study on five HBV/HDV co-infected patients 
three years later, 4.9% of the codons were reported to be under positive selection 73. 
In our study, 10.6 % of the codons (23 residues) were under diversifying positive 
selection, which is higher than anticipated from previous reports. The positively 
selected domains are located in the cytotoxic T-cells and B-cells epitopes, both 
relevant for cellular and humoral adaptive immune responses, respectively. Since 
other reports about the varying codons of HDAg also referred to the immunogenic 
domain of these alterations, these mutations may aid the virus to escape from the 
host’s immune response 28,72,73,80. Further studies should determine the functional 
consequences of HDV mutations for antigen processing and presentation or 
recognition by CD8 T or B lymphocytes. 
Unlike HDV, the Ag loop of HBV, which is the immunodominant region of 
HBsAg, remained preserved from amino acid substitutions in our study. Our in vitro 
experiments indicated a significant increase in HDV secretion in the presence of 
sG145R or sP120T mutations. A modified positioning of HBsAg-Ag loop might be an 
explanation for this observation. During HBV infection, approximately half of the 
HBsAg molecules remain non-glycosylated at their N-glycosylation sites, which is 
suggested to be due to the cytoplasmic orientation of major antigenic determinants 
32,99. This positioning provides an interaction opportunity between the non-
glycosylated-Ag loop and HDV-RNP 32. Moreover, due to the proximity of sG-145 and 
sP-120 with glycosylation sites on the surface proteins (sN-4, sN-146), mutations of 
these residues may affect the lateral S-S interactions of antigenic determinants with 
luminal orientation, which occur differently for HBV and HDV due to their particle 
sizes 33.  
Discussion 
___________________________________________________________________ 
69 
 
Likewise, our findings indicated a distinct mutational pattern arising at the 
domains of S-HBsAg with cytosolic orientation in double infected individuals 63,100. 
Based on previous reports, these domains known as CYL-I (residues 24 to 80) and -II 
(residues 193 to 201) in S-HBsAg are in direct interaction with HDV RNP, due to their 
cytosolic orientation in ER membrane 46,64. The importance of S-HBsAg residues 24 
to 28 and 56 to 80 for HDV secretion has been shown in previous studies 46,64,101. It 
was also shown that a C-terminal truncation of HBsAg by 50 amino acids inhibits 
HDV envelopment and secretion 101. Besides containing the CYL-II, the C-terminal 
domain of S protein mediates HBsAg glycosylation which facilitates HDV assembly 
and also includes tryptophan residues at positions 196, 199 and 201 whose 
interaction with HDAg has been previously shown 63,100,102. Experimental data 
revealed that most of the mutations in these domains are unfavorable for HDV 
secretion or infectivity, but tolerable for HBV SVP formation, which supports the 
concept that HBV can maintain its replication by not allowing HDV to use altered 
HBsAg resources 63,64,100.  
The two commonly seen LAM-resistance mutations, rtM204I and rtM204V that 
are associated with sW196L/S/Stop (in our study to sW196S) and sI195M, 
respectively, are reported to highly reduce HDV secretion 63,102. There was also a 
remarkable reduction in HBV secretion in our study, when LAM-resistance mutants 
were transfected with HDV. This reduction was restored to WT levels when sG145R 
and sP120T were simultaneously present, meaning that the two S protein mutations 
have positive influences on HBV and HDV encapsidation and release by improving 
the reduced secretion competence of LAM-resistance mutations. 
Considering the positive selection process on targeting immunodominant 
epitopes of L-HDAg and cytosolic domains of the S protein, it is very likely that each 
of the viruses is imposed by different challenging conditions and limiting items. 
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Moreover, since our and others experimental data indicate a drastic effect of 
most of the mutations in HBsAg cytosolic domains on HDV secretion or infectivity, 
while a tolerable outcome for HBV SVP formation, it is expected that HBV persist its 
replication by not allowing HDV to use altered HBsAg resources 63,64,100.  
7.4 Role and frequency of HBV-PC and -BCP mutations in HDV infection 
In our patient cohort, all HBV/HDV infected patients were HBeAg negative. 
While PC and BCP mutations were frequently found in mono-infected control 
patients, as expected 24, the BCP mutations occurred at very low frequency in 
HBV/HDV infected patients with detectable HBV-DNA. In agreement to this clinical 
observation, HBV replication and secretion was significantly reduced in HBV strains 
containing PC or BCP mutations in HBV/HDV co-transfection experiments. Although 
the studied BCP/PC mutations (A1762T/G1764A and G1896A), alone or in 
combination with LAM-resistance, resulted in a significant increase in HBV viremia in 
HBV-mono-infected patients and in cell culture models 12,37, presence of these 
mutations in the HBV genome of patients co-infected with HDV is accompanied with 
lower levels of HBV DNA in both serum and liver 12. Our sequence analysis thus 
confirmed the prior studies reporting a predominance of wild type precore HBV and 
lower frequency of BCP mutations in HBeAg negative patients in HBV/HDV co-
infections 103-105. From a molecular perspective, the interaction of HDAg with HBV 
Enh I and II to trans-repress HBV replication has been shown 106. It is therefore 
possible that the altered sequence of BCP and PC domains provide a new interaction 
site for HDV proteins or intermediate complexes to bind and exert their inhibitory 
effects, for example, by changing the transcriptional factor binding. Replication 
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reduction may also be due to the modified structure of HBx protein, which overlaps 
with the BCP domain 37. Interestingly, the synergistic activation of serum response 
element (SRE)-dependent pathways was reported for HBx and L-HDAg proteins 107. 
This at least reveals the presence of common or cross-linked transcriptional 
pathways, which may provide another site of competition for the two viruses, 
especially when one of the key proteins (like HBx protein) is mutated.  
8 Conclusions and outlook 
From a clinical point of view, delta hepatitis is the most severe form of chronic 
hepatitis, oftentimes resulting in rapid liver disease progression and life-threatening 
complications 1,5. This is also reflected by the high rate (>50%) of liver cirrhosis in the 
patient cohort analysed in this study.  
In this study, I observed that, despite of the high rate of mutations in HDAg, 
most of the PTM sites are conserved among HDV isolates. Moreover, significant 
positive changes were observed in the cytotoxic T-cells and B-cells epitopes, which 
indicate an induced pressure by cellular and humoral immune responses against 
HDAg.  
To which extent the molecular alterations observed in our comprehensive 
sequence analysis of HDV isolates impact the clinical course of liver disease needs 
to be investigated. This holds especially true for the relatively high diversity in the L-
HDAg amino acid sequence in the immunogenic epitopes, as well as changes in 
PTM sites and the C-terminal domain of L-HDAg which affects not only HDV 
packaging but also HBV replication through a trans-controlling mechanism.   
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Figure 16: HDV inhibits HBV replication through competitive or preventive mechanisms 
The inhibitory effects of HDV over HBV replication may occur through different mechanisms. One 
approach is to limit HBV envelopment through utilizing HBsAg resources. Some mutations in HBs 
domain may aid HBV to escape this inhibitory effect (A). While no accurate promoter sequence has 
been defined in the HDV genome, however, RNA polymerase II employment for HDV-RNA 
amplification in the presence of S-HDAg is reported 
108
, which may result in reduced transcription from 
HBV promoters (B). Another possible mechanism for low replication of HBV isolates especially with 
BCP or PC mutations in the presence of HDV is that the altered structure of HBx protein is no longer 
competent to activate transcription of HBV genome. As HDV proteins inhibit HBV replication through 
binding to its enhancer elements (Enh I, II) 
106
, it is also likely that BCP/PC mutations provide another 
position for these proteins to connect and hinder RNA-transcription from HBV genome.  
Enh: enhancer, NCP: nucleocapsid, RNA Pol: RNA polymerase, RNP: ribonucleoprotein, TF: 
transcription factor. 
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Our study also indicates that HDV endorses its inhibitory effect over HBV 
replication through competitive or preventive mechanisms (Figure 16). These include 
acquisition of HBV surface protein resources (Figure 16A), employing cellular 
transcription machinery (Figure 16B) and direct controlling of HBV transcription 
promoters or enhancer elements through L-HDAg (Figure 16C).  
These forces may endorse different selective adaptations in HBV, including 
amino acid changes at interaction sites with HDV and assortment of isolates with 
preferentially wild type BCP domain to escape inhibitory effects of HDV on its 
replication. Increased understanding of the molecular interactions between HBV and 
HDV may help to design novel drugs specifically targeting critical sites in both viruses 
and advance current therapeutic strategies for delta hepatitis. 
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